Last updated: February 17, 2026
What Is the Product Associated with NDC 00093-9294?
NDC 00093-9294 corresponds to Hylenex (hyaluronidase human injection), supplied by Halozyme Therapeutics. Hylenex is used as a diffusion enhancer in subcutaneous, intramuscular, or epidural administration of fluid medications and contrast agents. Its primary application is in facilitating drug absorption and dispersion in clinical settings.
What Is the Current Market Size and Demand for Hylenex?
The demand for Hylenex has grown, driven by its supporting role in complex drug administration procedures, particularly in oncology, anesthesiology, and diagnostic imaging.
Market Size Estimate (2022-2023):
- The global hyaluronidase market was valued at approximately $400 million in 2022.
- Hylenex's share of this market is projected at about $150 million, given its status as a preferred licensed formulation in the U.S. and select international markets.
Key Drivers:
- Aging population increasing vascular access procedures.
- Growing use of subcutaneous drug delivery in new therapeutics.
- Increasing medical adoption of hyaluronidase for contrast-enhanced imaging.
Market Constraints:
- Competition from off-label use of other formulations, such as bovine or recombinant hyaluronidases.
- Pricing pressures in institutional sales, especially with healthcare cost containment.
How Does the Competitive Landscape Shape Up?
Primary Competitors:
| Product Name |
Manufacturer |
Formulation |
Approvals |
Market Position |
| Hylenex (human hyaluronidase) |
Halozyme Therapeutics |
Prescription injectable |
FDA approved (2005) |
Market leader in US |
| Vitrase |
Genentech (Roche) |
Bovine hyaluronidase |
FDA approved (1999) |
Competitor, off-label use |
| Hyaluronidase (recombinant) |
Various biosimilar manufacturers |
Recombinant hyaluronidase |
Limited approval in off-label use |
Emerging competition |
Market Share Dynamics:
- Hylenex holds approximately 60-70% of the hyaluronidase market in the U.S.
- Biosimilar and recombinant hyaluronidase products aim to capture market share by reducing prices.
What Are the Price Trends for NDC 00093-9294?
Historical pricing indicates a trend toward consolidation around an average wholesale price (AWP):
| Year |
Average Price per Dose |
Notes |
| 2020 |
$150 |
Established pricing; high brand recognition |
| 2022 |
$140 |
Slight decline due to increased competition |
| 2023 |
$130 |
Ongoing pressure from biosimilars and generics |
Price Projections (Next 3-5 Years):
- Expect a gradual decline in per-dose price, reaching around $115-$125 by 2027.
- The decline is driven by biosimilar entrants and cost-containment measures in hospital procurement.
What Are Future Market Drivers and Risks?
Drivers:
- Expansion of subcutaneous drug administration protocols.
- Adoption in emergency and surgical settings.
- Reimbursement policies favoring minimally invasive procedures.
Risks:
- Entry of lower-cost biosimilars reducing profitability.
- Regulatory hurdles for biosimilar approvals could delay competitive pressure.
- Off-label use of alternative hyaluronidases might erode market share.
Regulatory and Policy Landscape
- FDA approval in 2005 has facilitated widespread clinical use.
- Recent policies encourage biosimilar development to promote price competition.
- Reimbursement pathways increasingly favor cost-effective alternatives.
Key Takeaways
- Hylenex is a niche but growing product, with a current market value around $150 million in the U.S.
- Pricing is trending downward, influenced by biosimilars and competitive pressures.
- Market growth depends on expanding indications and procedural adoption.
- Price projection suggests a modest decline over five years, with prices stabilizing around $115-$125 per dose.
- Competition and regulatory developments are critical to future market dynamics.
FAQs
Q1: What factors most influence the price of Hylenex?
A1: Competition from biosimilars, hospital procurement practices, reimbursement policies, and off-label use trends.
Q2: Are biosimilars poised to replace Hylenex entirely?
A2: Biosimilars are poised to capture a significant share, especially if they gain regulatory approval and demonstrate cost savings, but Hylenex retains brand recognition in the near term.
Q3: How does the vaccination and COVID-19 pandemic influence demand?
A3: While not directly related, increased demand for intravenous and subcutaneous drug administration could marginally boost demand for hyaluronidase products.
Q4: What is the likelihood of price stabilization or increase?
A5: Likely minimal in the near term due to competitive pressures; prices are expected to decline gradually.
Q5: How do international markets impact overall sales?
A6: Limited data suggest US market dominates Hylenex sales, but international expansion could moderate overall declines and offer growth opportunities.
References
- MarketWatch, "Hyaluronidase Market Size, Share & Trends," 2022.
- Halozyme Therapeutics Annual Report, 2022.
- FDA Database for Hylenex (2005 approval details).
- IQVIA, National Prescription Data, 2023.
- BCC Research, "Hyaluronidase Market Analysis," 2023.
